PSIAC
Sad Pill Bild Bildrechte: © spinetta / Fotolia

Oops!

Sie verwenden eine veraltete Version Ihres Internetbrowsers und können nicht auf die Inhalte der Seite zugreifen.
Bitte aktualisieren Sie Ihre Browserversion.

PSIAC

Literaturverzeichnis

Erweiterte Suche
Valdes L. Arch Pediatr. Jun 1997; 4(6): 535-7 Pubmed [8948]
Valdes M. J Affect Disord. Mar 2019; 246: 861-866 Pubmed [9888]
Vale JA. Lancet. Jun 1991; 337(8756): 1552 Pubmed [1279]
Valin N. J Int Assoc Physicians AIDS Care (Chic). Mar 2009; 8(2): 113-21 Pubmed [6380]
Valk-Swinkels CG. Ned Tijdschr Geneeskd. Jan 2013; 157(28): A5667 Pubmed [6215]
Vallée A. Aging (Albany NY). Feb 2020; 12(3): 3095-3113 Pubmed [11454]
Vallejo R. Pain Physician. Jul 2011; 14(4): E343-60 Pubmed [3301]
Valsalan VC. Br Med J (Clin Res Ed). Jul 1982; 285(6337): 261-2 Pubmed, Volltext [6788]
Van Berkel MA. Pharmacotherapy. Jun 2013; 33(6): e96-100 Pubmed [6132]
van Breemen RB. Fitoterapia. Jan 2011; 82(1): 38-43 Pubmed [12297]
van Breemen RB. J Agric Food Chem. May 2020; 68(18): 5212-5220 Pubmed [9109]
van Dalem J. BMJ. Jul 2016; 354: i3625 Pubmed, Volltext, DOI [9026]
Van de Velde V. Drugs R D. Mar 2013; 13(1): 43-51 Pubmed [14120]
van de Wetering-Krebbers SF. Drug Metab Dispos. Apr 2011; 39(4): 580-90 Pubmed [250]
van den Bemt PM. Pharm World Sci. Oct 2002; 24(5): 201-4 Pubmed [11830]
van den Berg MJ. Am J Ther. Jan 2016; 23(1): e246-8 Pubmed [1592]
Van den Bergh A. Clin Pharmacokinet. Sep 2020; 59(9): 1149-1160 Pubmed [11495]
Van der Auwera P. J Antimicrob Chemother. Nov 1993; 32 Suppl B: 103-15 Pubmed [5908]
van der Bol JM. Clin Cancer Res. Jan 2010; 16(2): 736-42 Pubmed [5010]
Van der Heijden KB. J Am Acad Child Adolesc Psychiatry. Feb 2007; 46(2): 233-41 Pubmed [11710]
van der Klauw MM. Arch Intern Med. Feb 1999; 159(4): 369-74 Pubmed [9089]
van der Kuy PH. BMJ. Feb 1998; 316(7129): 441 Pubmed, Volltext [1954]
van der Lee M. Antivir Ther. Jan 2007; 12(7): 1127-32 Pubmed [6482]
van der Lee MJ. Antimicrob Agents Chemother. Nov 2007; 51(11): 4098-104 Pubmed, Volltext, DOI [10143]
van der Lee MJ. Clin Pharmacol Ther. Aug 2006; 80(2): 159-68 Pubmed [8755]
van der Sandt IC. AIDS. Mar 2001; 15(4): 483-91 Pubmed [4997]
van der Velden W. Neth J Med. May 2008; 66(5): 204-6 Pubmed [5870]
van der Watt JJ. Int J Tuberc Lung Dis. Nov 2015; 19(11): 1312-9 Pubmed [9404]
van der Weide K. J Clin Psychopharmacol. Jun 2015; 35(3): 228-36 Pubmed [193]
van der Zalm IJB. J Med Case Rep. Jun 2020; 14(1): 83 Pubmed [11309]
van Dijkman SC. Br J Clin Pharmacol. Jan 2018; 84(1): 97-111 Pubmed, Volltext, DOI [9427]
Van Es MA. Amyotroph Lateral Scler Frontotemporal Degener. Nov 2020; 21(7-8): 584-592 Pubmed [11457]
van Giersbergen PL. Clin Pharmacol Ther. Mar 2007; 81(3): 414-9 Pubmed [4289]
van Giersbergen PL. Int J Clin Pharmacol Ther. Mar 2006; 44(3): 113-8 Pubmed [4287]
van Gorp F. Br J Clin Pharmacol. Mar 2012; 73(3): 402-10 Pubmed [13801]
van Haarst AD. Clin Pharmacol Ther. Nov 1998; 64(5): 542-6 Pubmed [5324]
van Harten et al. Eur Neuropsychopharmacol (1992) 2, 381 [1462]
van Harten J. Clin Pharmacokinet. Jan 1995; 29 Suppl 1: 1-9 Pubmed [325]
van Harten J. Clin Pharmacol Ther. Oct 1992; 52(4): 427-35 Pubmed [1457]
van Heeswijk RP. Antivir Ther. Jan 2013; 18(4): 553-60 Pubmed [6322]
van Heeswijk RP. J Antimicrob Chemother. Sep 2014; 69(9): 2310-8 Pubmed [5184]
van Heeswijk RP. J Clin Pharmacol. Jul 2006; 46(7): 758-67 Pubmed [461]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010;. [7391]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010;. [7392]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010;. [7393]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7394]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7395]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7396]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7397]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7398]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7399]
van Helvoort M. Int Clin Psychopharmacol. Sep 2019; 34(5): 269-272 Pubmed [9131]
van Hoppe S. Pharmacol Res. Aug 2019; 146: 104297 Pubmed [11487]
van Hoppe S. Pharmacol Res. Jun 2017; 120: 43-50 Pubmed [7756]
Van Kammen DP. Psychopharmacologia. Nov 1975; 44(3): 215-24 Pubmed [1743]
van Kan HJ. Biopharm Drug Dispos. Apr 2008; 29(3): 139-44 Pubmed [11375]
van Laar MW. Psychopharmacology (Berl). Aug 2002; 162(4): 351-63 Pubmed [11246]
van Leeuwen DJ. Ned Tijdschr Geneeskd. Mar 1986; 130(12): 548-50 Pubmed [6091]
Van LM. J Psychopharmacol. Nov 2006; 20(6): 834-41 Pubmed [13738]
van Luin M. AIDS. May 2010; 24(8): 1223-6 Pubmed [6421]
van Luin M. J Acquir Immune Defic Syndr. Sep 2010; 55(1): 82-6 Pubmed [7378]
van Luin M. J Clin Pharmacol. Oct 2009; 49(10): 1220-7 Pubmed [2953]
van Maarseveen EM. AIDS Patient Care STDS. Oct 2012; 26(10): 568-81 Pubmed [8981]
van Meerten E. Drug Saf. Mar 1995; 12(3): 168-82 Pubmed [7341]
van Nuland M. Prostate Cancer Prostatic Dis. Jun 2020; 23(2): 244-251 Pubmed [12403]
van Praag HM. Biol Psychiatry. Feb 1987; 22(2): 205-12 Pubmed [8281]
Van Rooij J. Br J Clin Pharmacol. Jun 1993; 35(6): 661-3 Pubmed, Volltext, DOI [8584]
van Schaik RH. Invest New Drugs. Dec 2005; 23(6): 513-22 Pubmed [13877]
van Seyen M. Clin Pharmacol Ther. Nov 2019; 106(5): 1093-1098 Pubmed [8058]
Van Slooten AD. DICP. Jun 1991; 25(6): 578-82 Pubmed [5833]
Van Strater AC. Int Clin Psychopharmacol. Mar 2012; 27(2): 121-4 Pubmed [1129]
van Waterschoot RA. Br J Pharmacol. Jul 2010; 160(5): 1224-33 Pubmed, Volltext, DOI [8777]
van Wieringen A. Clin Pharmacokinet. Apr 1990; 18(4): 332-8 Pubmed [2451]
van Wieringen A. Neurology. Sep 1983; 33(9): 1227-8 Pubmed [9275]
van Zuilekom S. Tijdschr Psychiatr. Jan 2013; 55(12): 955-9 Pubmed [6999]
van Zwieten PA. Arch Int Pharmacodyn Ther. Mar 1975; 214(1): 12-30 Pubmed [1941]
Vanakoski J. Eur J Clin Pharmacol. Jan 1996; 50(6): 501-8 Pubmed [1877]
Vance KM. Nutrition. Jul 2014; 30(7-8 Suppl): S37-42 Pubmed [13708]
Vandel et al. Pharm Res 1995;31(6):347-353 [1025]
Vandel et al. Therapie (1990) 45, 21 [1027]
Vandel P. Encephale. Jan 1999; 25(1): 67-71 Pubmed [3182]
Vandel P. Encephale. Nov 1999; 25(6): 672-3 Pubmed [10122]
Vandel P. Hum Psychopharmacol. Jul 2004; 19(5): 293-8 Pubmed [8213]
Vandel S. Pharmacol Res. Jun 1995; 31(6): 347-53 Pubmed [1480]
Vandel S. Ther Drug Monit. Jan 1988; 10(4): 386-9 Pubmed [2421]
Vandel. Therapie (1990) 45, 21 [544]
VandenBrink BM. Drug Metab Dispos. Jan 2012; 40(1): 47-53 Pubmed [3488]
Vandenbussche C. Arch Toxicol. Apr 2018; 92(4): 1539-1550 Pubmed [7889]
Vandevelde C. Pharmacotherapy. Jan 1991; 11(1): 88-9 Pubmed [6210]
VanLandingham KE. J Clin Pharmacol. Oct 2020; 60(10): 1304-1313 Pubmed, Volltext, DOI [9843]
VARAGIC V. Arch Int Pharmacodyn Ther. Apr 1958; 114(3-4): 426-34 Pubmed [9402]
Varanese S. Mov Disord. Mar 2010; 25(4): 508-10 Pubmed [9917]
Vardar MK, Kovalak EE. Bagcilar Med Bul. Sep 2022; 7: 288–290 Pubmed [13449]
Varhe A. Br J Clin Pharmacol. Apr 1996; 41(4): 319-23 Pubmed, Volltext, DOI [2398]
Varhe A. Br J Clin Pharmacol. Oct 1996; 42(4): 465-70 Pubmed, Volltext, DOI [2394]
Varhe A. Clin Pharmacol Ther. Apr 1996; 59(4): 369-75 Pubmed [2400]
Varhe A. Clin Pharmacol Ther. Dec 1994; 56(6 Pt 1): 601-7 Pubmed [2396]
Varis et al. Clin Pharmacol Therap 2000;68(5):487-494 [2972]
Varis T. Clin Pharmacol Ther. Nov 2000; 68(5): 487-94 Pubmed [4493]
Varsaldi F. Eur J Clin Pharmacol. Sep 2006; 62(9): 721-6 Pubmed [113]